如Paxlovid主要成分为奈玛特韦和利托那韦,而目前已有报道称,在接受利托那韦和吸入或鼻喷糖皮质激素的患者中出现过全身糖皮质激素反应,包括库欣综合征和肾上腺抑制,且在经CYP3A代谢途径的其它糖皮质激素中也观察到类似反应,因此通常不建议两者联合使用,即使合用也应当考虑降低糖皮质激素剂量并密切监测全身或局部反应[12]...
对于慢性阻塞性肺病患者来说,担心出现Covid-19以及大流行对与其健康有关的社会基本功能和/或社会服务的影响,给他们的状况带来了额外的压力源。Covid-19大流行使慢性阻塞性肺病的常规管理和诊断更加困难,因为面对面咨询减少、进行肺量测定困难以及传统肺康复和家庭护理方案的困难。患者也面临着药物短缺的问题。(1)随...
[9]Aveyard P, Gao M, Lindson N, et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. Lancet Respir Med. 2021;9(8):909-923. [10]Therapeutics and COVID-19: Livin...
The FDA has approved a fixed-dose dual bronchodilator that combines glycopyrrolate and formoterol fumarate in a pressurized, metered-dose inhaler. The drug, marketed as Bevespi Aerosphere, is indicated for long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive ...
The immunology of long COVID Article 11 July 2023 References Barnes, P. J. Chronic obstructive pulmonary disease. N. Engl. J. Med. 343, 269–280 (2000).A general overview of the current understanding of the mechanisms and therapy of COPD. Article CAS PubMed Google Scholar Barnes, P....
We will address the following specific questions: Are patients with COPD at an increased risk of COVID-19? / Should COVID-19 be considered a COPD exacerbation? / What is the optimal medical treatment for a patient with COPD and COVID-19? / Which ventilatory support should be provided to ...
Introduction : The role of COPD in COVID-19 is not yet well understood. However, there is increasing evidence showing that COPD patients with COVID-19 have a higher risk of presenting a serious infection, a greater likelihood of requiring ICU support, and a higher mortality than other groups...
COVID-19患者中合并哮喘、慢性阻塞性肺疾病(COPD)和哮喘慢阻肺重叠(ACO)的患病率不同,死亡风险也不同。本文推介研究旨在通过系统综述和荟萃分析,评估哮喘、COPD和ACO作为合并症的患病率,并确定其在COVID-19患者中的死亡风险。 关键词:COVID-19;哮喘;慢性阻塞性肺疾病;哮喘合并慢阻肺 ...
Ask about vaccines you may need. Influenza (the flu), pneumonia, and COVID-19 can become life-threatening for a person who has COPD. Get a yearly flu vaccine as soon as recommended, usually in September or October. The pneumonia vaccine may be given every 5 years, or as directed. COVI...
【摘要】2019冠状病毒病(COVID-19)大流行是由严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2)引起的。男性、高龄和有合并症患者的临床结局(包括死亡率)更差。COPD患者由于易受病毒诱导而致急性加重、肺功能受损和相关合并症的高患病率而被纳入...